Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease.

Navarroza RV, Zamora LD, Navarra SV.

Int J Rheum Dis. 2019 Aug 19. doi: 10.1111/1756-185X.13683. [Epub ahead of print]

PMID:
31424178
2.

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.

van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.

Rheumatology (Oxford). 2019 Jul 13. pii: kez279. doi: 10.1093/rheumatology/kez279. [Epub ahead of print]

PMID:
31302695
3.

[Impact of the implementation of ICD-10 2016 version and Iris software on mortality statistics in Italy].

Orsi C, Navarra S, Frova L, Grande E, Marchetti S, Pappagallo M, Grippo F.

Epidemiol Prev. 2019 Mar-Jun;43(2-3):161-170. doi: 10.19191/EP19.2-3.P161.055. Italian.

PMID:
31293135
4.

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group.

Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9.

PMID:
30420324
5.

Development of the Asia Pacific Lupus Collaboration cohort.

Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Hao Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanaka Y, Bae SC, Lau CS, Hoi A, Nikpour M, Morand EF.

Int J Rheum Dis. 2019 Mar;22(3):425-433. doi: 10.1111/1756-185X.13431. Epub 2018 Nov 5.

PMID:
30398013
6.

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Costedoat-Chalumeau N, Houssiau F, Izmirly P, Guern VL, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard JF, Pineau C, Galicier L, Vollenhoven RV, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette JC, Petri M, Isenberg D.

Clin Pharmacol Ther. 2019 Aug;106(2):374-382. doi: 10.1002/cpt.1194. Epub 2018 Sep 2.

PMID:
30079582
7.

Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, Touma Z.

Arthritis Rheumatol. 2019 Jan;71(1):91-98. doi: 10.1002/art.40674. Epub 2018 Nov 26.

PMID:
30035365
8.

Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus.

Jolly M, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Weisman M, Clarke AE, Wallace D, Alarcón G.

Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23588. [Epub ahead of print]

9.

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K.

Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.

10.

Strong viral associations with SLE among Filipinos.

Vista ES, Weisman MH, Ishimori ML, Chen H, Bourn RL, Bruner BF, Hamijoyo L, Tanangunan RD, Gal NJ, Robertson JM, Harley JB, Guthridge JM, Navarra SV, James JA.

Lupus Sci Med. 2017 Jul 28;4(1):e000214. doi: 10.1136/lupus-2017-000214. eCollection 2017.

11.

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard JF, Pineau C, Galicier L, Van Vollenhoven R, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette JC, Petri M, Isenberg D.

Clin Pharmacol Ther. 2018 Jun;103(6):1074-1082. doi: 10.1002/cpt.885. Epub 2017 Nov 9.

12.

Disease-specific quality of life in patients with lupus nephritis.

Jolly M, Toloza S, Goker B, Clarke AE, Navarra SV, Wallace D, Weisman M, Mok CC.

Lupus. 2018 Feb;27(2):257-264. doi: 10.1177/0961203317717082. Epub 2017 Jul 20.

PMID:
28728507
13.

Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.

Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration.

Arthritis Res Ther. 2017 Mar 20;19(1):62. doi: 10.1186/s13075-017-1256-6.

14.

Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.

Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M.

Semin Arthritis Rheum. 2017 Jun;46(6):798-803. doi: 10.1016/j.semarthrit.2017.01.007. Epub 2017 Jan 18.

PMID:
28216192
15.

Development and implementation of Models of Care for musculoskeletal conditions in middle-income and low-income Asian countries.

Lim KK, Chan M, Navarra S, Haq SA, Lau CS.

Best Pract Res Clin Rheumatol. 2016 Jun;30(3):398-419. doi: 10.1016/j.berh.2016.08.007. Review.

PMID:
27886939
16.

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M.

Ann Rheum Dis. 2017 Mar;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24. Review.

17.

Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.

Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M; Asia-Pacific Lupus Collaboration.

Arthritis Res Ther. 2016 Nov 9;18(1):260.

18.

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.

Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W.

Arthritis Res Ther. 2016 Apr 2;18:82. doi: 10.1186/s13075-016-0981-6.

19.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).

Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration.

Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726. Epub 2015 Oct 12.

PMID:
26458737
20.

Biologic therapies in systemic lupus erythematosus.

Bernal CB, Zamora LD, Navarra SV.

Int J Rheum Dis. 2015 Feb;18(2):146-53. doi: 10.1111/1756-185X.12490. Review.

PMID:
25884458
21.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirják L, Derksen R, Dörner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M.

Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16.

22.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW.

Arthritis Rheumatol. 2014 Feb;66(2):480. doi: 10.1002/art.38251. No abstract available.

23.

Overview of lupus nephritis management guidelines and perspective from Asia.

Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen N, Chen SL, Chan TM; Asian Lupus Nephritis Network (ALNN).

Int J Rheum Dis. 2013 Dec;16(6):625-36. doi: 10.1111/1756-185X.12212. Epub 2013 Oct 31. Review.

PMID:
24382275
24.

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU.

Int J Rheum Dis. 2014 Mar;17(3):291-8. doi: 10.1111/1756-185X.12188. Epub 2013 Oct 16.

25.

Overview of lupus nephritis management guidelines and perspective from Asia.

Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen N, Chen SL, Chan TM; Asian Lupus Nephritis Network (ALNN).

Nephrology (Carlton). 2014 Jan;19(1):11-20. doi: 10.1111/nep.12136. Review.

PMID:
23876069
26.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

27.

Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines.

Navarra SV, Tanangunan RM, Mikolaitis-Preuss RA, Kosinski M, Block JA, Jolly M.

Lupus. 2013 Mar;22(3):262-7. doi: 10.1177/0961203312474086. Epub 2013 Jan 22.

PMID:
23340995
28.

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups.

Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4.

PMID:
23213069
29.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups.

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

30.

Systemic lupus erythematosus following HPV immunization or infection?

Soldevilla HF, Briones SF, Navarra SV.

Lupus. 2012 Feb;21(2):158-61. doi: 10.1177/0961203311429556.

PMID:
22235047
31.

Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G.

Fernando MM, Freudenberg J, Lee A, Morris DL, Boteva L, Rhodes B, Gonzalez-Escribano MF, Lopez-Nevot MA, Navarra SV, Gregersen PK, Martin J; IMAGEN, Vyse TJ.

Ann Rheum Dis. 2012 May;71(5):777-84. doi: 10.1136/annrheumdis-2011-200808. Epub 2012 Jan 10.

32.

Identity and ranking of colonic mesenchymal stromal cells.

Signore M, Cerio AM, Boe A, Pagliuca A, Zaottini V, Schiavoni I, Fedele G, Petti S, Navarra S, Ausiello CM, Pelosi E, Fatica A, Sorrentino A, Valtieri M.

J Cell Physiol. 2012 Sep;227(9):3291-300. doi: 10.1002/jcp.24027.

PMID:
22170005
33.

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Saccà M, Eramo A, De Maria R.

Cell Death Differ. 2012 May;19(5):768-78. doi: 10.1038/cdd.2011.170. Epub 2011 Nov 25.

34.

Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality.

Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):159-68. doi: 10.1002/acr.20683. Review.

35.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
36.

Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives.

Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, Holers VM, Weisman MH.

Lupus. 2011 Apr;20(5):537-43. doi: 10.1177/0961203310385164. Epub 2010 Dec 23.

PMID:
21183559
37.

Infections in systemic lupus erythematosus.

Navarra SV, Leynes MS.

Lupus. 2010 Oct;19(12):1419-24. doi: 10.1177/0961203310374486. Review.

PMID:
20947551
38.

Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness.

Soldevilla HF, Molina RM, Navarra SV.

Int J Rheum Dis. 2010 May;13(2):164-70. doi: 10.1111/j.1756-185X.2010.01473.x.

PMID:
20536602
39.

Salmonella infections in patients with systemic lupus erythematosus: a case series.

Gerona JG, Navarra SV.

Int J Rheum Dis. 2009 Dec;12(4):319-23. doi: 10.1111/j.1756-185X.2009.01440.x.

PMID:
20374369
40.

Central nervous system infections in Filipino patients with systemic lupus erythematosus.

Vargas PJ, King G, Navarra SV.

Int J Rheum Dis. 2009 Sep;12(3):234-8. doi: 10.1111/j.1756-185X.2009.01416.x.

PMID:
20374352
41.

Survey of vitamin D levels among post-menopausal Filipino women with osteoporosis.

Raso AA, Navarra SV, Li-Yu J, Torralba TP.

Int J Rheum Dis. 2009 Sep;12(3):225-9. doi: 10.1111/j.1756-185X.2009.01414.x.

PMID:
20374350
42.

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.

BonAdASIA Study Group, Kung AW, Rachman IA, Adam JM, Roeshadi D, Torralba T, Navarra S, Gamilla Z, Cañete A, de la Rosa M, Tsai K, Lin HY, Soong YK, Lan JL, Hsu HC, Tu ST, Lin RM, Yuktanandana P, Songpatanasilp T, Ngarmukos S, Soontrapa S, Soontrapa S, Rojanasthien S, Luevitoonvechkij S, Leerapan T, Albert A, Vanbelle S.

Int J Rheum Dis. 2009 Sep;12(3):216-24. doi: 10.1111/j.1756-185X.2009.01413.x.

PMID:
20374349
43.

Severe hip and knee pain in a man with chronic tophaceous gout.

Tolin MC, Navarra SV.

Int J Rheum Dis. 2009 Apr;12(1):57-60. doi: 10.1111/j.1756-185X.2009.01385.x.

PMID:
20374318
44.

Impact of systemic lupus erythematosus on health, family, and work: the patient perspective.

Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M.

Arthritis Care Res (Hoboken). 2010 Feb;62(2):266-73. doi: 10.1002/acr.20077.

45.

Gigantomastia in a patient with systemic lupus erythematosus successfully treated by reduction mammoplasty.

Lanzon AE, Navarra SV.

Lupus. 2009 Dec;18(14):1309-12. doi: 10.1177/0961203309106690. Epub 2009 Oct 22.

PMID:
19850663
46.

Lupus registries: evolution and challenges.

Lu LJ, Wallace DJ, Navarra SV, Weisman MH.

Semin Arthritis Rheum. 2010 Feb;39(4):224-45. doi: 10.1016/j.semarthrit.2008.08.009. Epub 2008 Nov 7. Review.

PMID:
18992923
47.

Lupus in the developing world--is it any different?

Tikly M, Navarra SV.

Best Pract Res Clin Rheumatol. 2008 Aug;22(4):643-55. doi: 10.1016/j.berh.2008.05.003. Review.

PMID:
18783742
48.

Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus.

Villamin CA, Navarra SV.

Mod Rheumatol. 2008;18(2):161-4. doi: 10.1007/s10165-008-0029-0. Epub 2008 Mar 4.

PMID:
18311532
49.

Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families.

Rhodes B, Wong A, Navarra SV, Villamin C, Vyse TJ.

Genes Immun. 2008 Mar;9(2):153-60. doi: 10.1038/sj.gene.6364459. Epub 2008 Jan 24.

50.

Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout.

Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM.

Curr Med Res Opin. 2007 Jul;23(7):1685-91.

PMID:
17588299

Supplemental Content

Loading ...
Support Center